These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 33107212)

  • 1. Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China.
    Yao Y; Zhang R; An T; Zhao X; Zhang J
    ESC Heart Fail; 2020 Dec; 7(6):3582-3592. PubMed ID: 33107212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China.
    Jiang Y; Zheng R; Sang H
    Front Pharmacol; 2021; 12():733681. PubMed ID: 34858172
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes.
    Abushanab D; Chbib S; Kaddoura R; Al Hail M; Abdul Rouf PV; El Kassem W; Shah J; Ravindran Nair RK; Al-Badriyeh D
    J Med Econ; 2024; 27(1):404-417. PubMed ID: 38390641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Dapagliflozin vs Empagliflozin for Treating Heart Failure With Reduced Ejection Fraction in the United States.
    Nechi RN; Rane A; Karaye RM; Ndikumukiza C; Alsahali S; Jatau AI; Zoni CR; Alanzi A; Karaye IM; Yunusa I
    Clin Ther; 2023 Jul; 45(7):627-632. PubMed ID: 37270374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-utility analysis of empagliflozin in heart failure patients with reduced and preserved ejection fraction in China.
    Tang Y; Sang H
    Front Pharmacol; 2022; 13():1030642. PubMed ID: 36386229
    [No Abstract]   [Full Text] [Related]  

  • 7. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction.
    Krittayaphong R; Permsuwan U
    Int J Cardiol; 2021 Jan; 322():183-190. PubMed ID: 32800910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region.
    Liao CT; Yang CT; Toh HS; Chang WT; Chang HY; Kuo FH; Lee MC; Hua YM; Tang HJ; Strong C; Ou HT
    Cardiovasc Diabetol; 2021 Oct; 20(1):204. PubMed ID: 34627231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study.
    Lu H; Shang P; Zhou D
    Front Pharmacol; 2023; 14():1155210. PubMed ID: 37771722
    [No Abstract]   [Full Text] [Related]  

  • 10. Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines.
    Mendoza VL; Tumanan-Mendoza BA; Punzalan FER
    ESC Heart Fail; 2021 Dec; 8(6):5132-5141. PubMed ID: 34494399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction.
    Isaza N; Calvachi P; Raber I; Liu CL; Bellows BK; Hernandez I; Shen C; Gavin MC; Garan AR; Kazi DS
    JAMA Netw Open; 2021 Jul; 4(7):e2114501. PubMed ID: 34313742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of empagliflozin as a treatment for heart failure with reduced ejection fraction: an analysis from the Chinese healthcare perspective.
    Lin X; Lin M; Liu M; Huang W; Nie X; Chen Z; Zheng B
    J Thorac Dis; 2022 May; 14(5):1588-1597. PubMed ID: 35693603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Utility Analysis of Vericiguat in Heart Failure with Reduced Ejection Fraction After Worsening Heart Failure Events in China.
    Chen P; Wang Y; Liu X; Yu J; Zheng X
    Am J Cardiovasc Drugs; 2024 May; 24(3):445-454. PubMed ID: 38619802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative value of dapagliflozin vs empagliflozin in patients with heart failure and preserved ejection fraction: A cost-effectiveness analysis.
    Rane A; Nechi RN; Imam M; Zoni CR; Ndikumukiza C; Karaye IM; Yunusa I; Alanzi A
    J Manag Care Spec Pharm; 2023 Sep; 29(9):1045-1053. PubMed ID: 37610112
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-utility analysis of add-on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction.
    Tang Y; Sang H
    ESC Heart Fail; 2023 Aug; 10(4):2524-2533. PubMed ID: 37290665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of dapagliflozin and empagliflozin for treatment of heart failure with reduced ejection fraction.
    Nguyen BN; Mital S; Bugden S; Nguyen HV
    Int J Cardiol; 2023 Apr; 376():83-89. PubMed ID: 36736672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF.
    McEwan P; Darlington O; McMurray JJV; Jhund PS; Docherty KF; Böhm M; Petrie MC; Bergenheim K; Qin L
    Eur J Heart Fail; 2020 Nov; 22(11):2147-2156. PubMed ID: 32749733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Adding Empagliflozin to Standard Treatment for Heart Failure with Preserved Ejection Fraction Patients in China.
    Lou Y; Hu T; Huang J
    Am J Cardiovasc Drugs; 2023 Jan; 23(1):47-57. PubMed ID: 36207658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction.
    Cohen LP; Isaza N; Hernandez I; Lewis GD; Ho JE; Fonarow GC; Kazi DS; Bellows BK
    JAMA Cardiol; 2023 May; 8(5):419-428. PubMed ID: 36870047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacubitril/Valsartan for Heart Failure with Preserved Ejection Fraction: A Cost-Effectiveness Analysis from the Perspective of the Chinese Healthcare System.
    Wang Z; Lou Y; Wang Q; Sun M; Li X; Wang Y; Wang Y
    Clin Drug Investig; 2023 Apr; 43(4):265-275. PubMed ID: 36976423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.